Phase III Study Of Rituxan In Lupus Nephritis Did Not Meet Primary Endpoint – 1st Edition
Genentech, Inc. (NYSE:DNA) and Biogen Idec (Nasdaq:BIIB) announced that a Phase III study of Rituxan® (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks. The primary endpoint evaluated improvements in kidney response as measured by standard laboratory tests used to assess kidney health.
By medicalnewstoday.com
